Danaher expects Q4 2025 revenue and full-year adjusted EPS to finish at the high end of prior guidance, driven by strong performance in bioprocessing, life sciences, and diagnostics. Its subsidiary, Integrated DNA Technologies, announced a collaboration with Ansa Biotechnologies to expand its synthetic biology portfolio. The company anticipates a strong 2026, citing its diagnostic portfolio's focus on attractive areas like molecular testing and core lab, and noted rebounding demand.